10-Q: AppYea Inc. Reports Q3 2024 Results, Revenue Growth and Continued Losses

AppYea Inc. reported a small amount of revenue from product sales in Q3 2024, but continues to experience significant losses and a going concern qualification.

Summary

• AppYea Inc. reported its financial results for the third quarter of 2024, showing a net loss of $512,000 for the three months ended September 30, 2024, and a net loss of $1,575,000 for the nine months ended September 30, 2024.
• The company generated $1,000 in revenue for the three months ended September 30, 2024 and $16,000 for the nine months ended September 30, 2024, all from sales of its AppySleep wristband.
• Research and development expenses increased to $159,000 for the three months and $316,000 for the nine months ended September 30, 2024, due to increased investment in product development.
• Sales and marketing expenses also increased to $153,000 for the three months and $310,000 for the nine months ended September 30, 2024, reflecting increased marketing efforts.
• The company's accumulated deficit reached $7,901,000 as of September 30, 2024, and it has a stockholders deficiency of $2,166,000.
• AppYea has a going concern qualification from its auditors, indicating substantial doubt about its ability to continue as a going concern.
• The company is actively seeking additional capital to fund its operations and continue its product development.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with significant losses, a going concern qualification, and ineffective internal controls. While there is some positive news regarding product launches and revenue generation, the overall sentiment is negative due to the company's financial instability and reliance on external funding.

Positives

• The company generated its first revenue from product sales, with $16,000 in revenue for the nine months ended September 30, 2024.
• The AppySleep iOS and Android versions were launched during the third quarter of 2024.
• The company is actively developing its AppySleep LAB and AppySleep PRO products for sleep apnea diagnosis and treatment.
• The company has established a logistical distribution facility in the US.

Negatives

• The company continues to experience significant losses, with a net loss of $1,575,000 for the nine months ended September 30, 2024.
• The company has a substantial accumulated deficit of $7,901,000 and a stockholders deficiency of $2,166,000.
• The company's auditors have included a going concern qualification, indicating substantial doubt about its ability to continue as a going concern.
• The company's current liabilities significantly exceed its current assets.
• The company's disclosure controls and procedures were deemed not effective as of September 30, 2024.
• The company has identified a material weakness in its internal controls related to segregation of duties.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• There is no assurance that the company will be successful in obtaining adequate financing.
• The company may be required to reduce the scope, delay, or eliminate some or all of its planned operations if it cannot raise sufficient capital.
• The company is involved in a legal proceeding that could have an adverse effect on its subsidiary SleepX and/or the company.
• The company's internal controls over financial reporting are not effective, which could lead to material misstatements in its financial statements.
• The company's products are still in development and may not achieve regulatory approval or market acceptance.

Future Outlook

The company intends to continue to finance its operating activities by raising capital and plans to file a 510(k) FDA submission for the AppySleep LAB app in 2025 and an FDA process for AppySleep PRO in 2026. The company aims to establish its technology as the gold standard for targeted sectors over the next five years.

Management Comments

• Management believes that funds on hand will enable the company to fund operations through December 2024.
• Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives.
• Management is composed of a small number of professionals resulting in a situation where limitations on segregation of duties exist.

Industry Context

The global anti-snoring treatment market is expected to grow to USD 8.6 billion by 2028, and the global sleep apnea device market is expected to reach USD 6.1 billion by 2028. AppYea is positioning itself to capture a share of this growing market with its wearable monitoring and treatment solutions.

Comparison to Industry Standards

• The company's revenue of $16,000 for the nine months ended September 30, 2024, is very low compared to established medical device companies in the sleep apnea and snoring market, such as ResMed (RMD) and Philips (PHG), which generate billions in annual revenue.
• AppYea's significant losses and going concern qualification are not typical for established companies in the industry, but are common for early-stage companies focused on research and development.
• The company's reliance on external funding is also typical for early-stage companies, while established companies often have strong cash flows from operations.
• The company's focus on AI-based solutions aligns with the industry trend of incorporating advanced technologies for improved diagnosis and treatment.

Management Changes

Legal Proceedings

• A lawsuit was filed in the Tel Aviv Magistrates Court against the company's Chairman and other related parties, alleging breach of partnership and loan agreements.
• The lawsuit was transferred to the economic department of the District Court in Tel Aviv.
• The parties are considering mediation before the ruling.

Related Party Transactions

• SleepX borrowed from Nexense Technologies USA. Inc., a company majority owned by the company's Chairman, Boris Molchadsky.
• The company has short-term loans from related parties totaling $79,000.
• The company has transactions with related parties including salaries, related costs, and management fees.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern qualification.
• Employees may be impacted by potential cost reduction measures or delays in development programs.
• Customers may be affected by potential delays in product development or availability.
• Creditors face increased risk due to the company's financial difficulties.

Next Steps

• The company plans to continue to develop its AppySleep LAB and AppySleep PRO products.
• The company intends to file a 510(k) FDA submission for the AppySleep LAB app in 2025.
• The company plans to pursue an FDA process for AppySleep PRO in 2026.
• The company will continue to seek additional capital to fund its operations.

Key Dates

Keywords

sleep apnea, snoring, wearable technology, biofeedback, digital health, medical devices, AppySleep, financial results, going concern, stock options